SecBot SecBot

Stop STALLING Act

S. 148 Sen. Amy Klobuchar (D-MN) In committee
Bill text PDF
  1. Introduced Jan 30
  2. Committee Jan 30
  3. Passed Senate Next
  4. Passed House Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Jan 30, 2023Next: Senate vote
1337d ago Mar 1, 2023: Placed on Senate Legislative Calendar under General Orders. Calendar No. 21.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
3companies, 4 filings
Subscribe to see spend
Member trades
8trades in the last 90 days
Subscribe to see who
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

3 companies
Companies by sector
Biotech & Pharma 3
Search all 3 companies, their asks and price moves Subscribe

Summary

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act

Full summary2 paragraphs

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

Library of Congress summary, Mar 1, 2023

Summary versions
  • Reported to SenateMar 1, 2023
  • Introduced in SenateJan 30, 2023

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.